Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Alterity Therapeutics Ltd (ADR - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ATHE
Nasdaq
8731
https://alteritytherapeutics.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Alterity Therapeutics Ltd (ADR
Alterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting
- Apr 17th, 2024 11:25 am
Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024
- Apr 10th, 2024 11:25 am
Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund
- Mar 26th, 2024 2:25 pm
Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting
- Feb 20th, 2024 3:25 pm
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review
- Feb 6th, 2024 12:25 pm
Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This Week
- Jan 29th, 2024 12:24 pm
Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones
- Jan 22nd, 2024 12:25 pm
Alterity Therapeutics Appoints Phillip Hains as Chief Financial Officer
- Dec 21st, 2023 5:30 am
Alterity (ATHE) Up on Preclinical Parkinson's Treatment Data
- Dec 5th, 2023 6:19 pm
Alterity Therapeutics to Host Webcast to Discuss ATH434 Efficacy Data in Primates and Recent Clinical Progress
- Dec 4th, 2023 9:35 pm
Biotech Alterity Jumps On Upbeat Parkinson's Treatment Clinical Trial Data
- Dec 4th, 2023 3:58 pm
Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s Disease
- Dec 4th, 2023 12:25 pm
Alterity Therapeutics Announces Presentation of Novel Biomarker Data for Evaluation of Multiple System Atrophy
- Nov 27th, 2023 12:25 pm
Alterity Therapeutics Limited's (ASX:ATH) CEO Compensation Is Looking A Bit Stretched At The Moment
- Nov 22nd, 2023 8:58 pm
Alterity Therapeutics Announces Presentation of New Data Demonstrating Novel Mechanisms of ATH434
- Nov 16th, 2023 12:25 pm
Alterity Therapeutics Completes Enrolment in ATH434-201 Phase 2 Clinical Trial in Multiple System Atrophy
- Nov 8th, 2023 12:25 pm
Appendix 4C – Q1 FY24 Quarterly Cash Flow Report
- Oct 30th, 2023 11:25 am
Alterity Therapeutics Presents New Data on Multiple System Atrophy, a Rare Parkinsonian Disorder
- Aug 31st, 2023 11:25 am
Alterity Therapeutics Granted New Composition of Matter Patent in Europe for Neurodegenerative Diseases including Parkinson’s and Alzheimer’s
- Aug 23rd, 2023 11:25 am
Alterity Therapeutics Rare Disease Natural History Study to be Featured at the International Congress of Parkinson’s Disease and Movement Disorders
- Aug 22nd, 2023 11:25 am
Scroll